IL109558A - מבני ד.נ.א. הנגזרים מוירוס sv40 הכוללים רצפי ד.נ.א. חיצוניים - Google Patents

מבני ד.נ.א. הנגזרים מוירוס sv40 הכוללים רצפי ד.נ.א. חיצוניים

Info

Publication number: IL109558A
Authority: IL; Israel
Prior art keywords: cells; dna; cell; gene; dna construct
Prior art date: 1994-05-04

Application number

IL10955894A

Other languages

English (en)

Other versions

IL109558A0 (en

Inventor

Ariella Oppenheim

Nava Dalyot

Original Assignee

Yissum Res Dev Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-04

Filing date

1994-05-04

Publication date

2004-08-31

1994-05-04 Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co

1994-05-04 Priority to IL10955894A priority Critical patent/IL109558A/he

1994-08-26 Publication of IL109558A0 publication Critical patent/IL109558A0/xx

1995-05-04 Priority to AU24350/95A priority patent/AU2435095A/en

1995-05-04 Priority to CA002189582A priority patent/CA2189582A1/en

1995-05-04 Priority to EP95918395A priority patent/EP0772688A1/en

1995-05-04 Priority to US08/737,047 priority patent/US6090608A/en

1995-05-04 Priority to PCT/US1995/005595 priority patent/WO1995030762A1/en

1995-05-04 Priority to GB9622965A priority patent/GB2303137A/en

2004-08-31 Publication of IL109558A publication Critical patent/IL109558A/he

Links

108020004414 DNA Proteins 0.000 title claims abstract description 149
108091029865 Exogenous DNA Proteins 0.000 title claims abstract description 61
108090000623 proteins and genes Proteins 0.000 claims abstract description 128
230000014509 gene expression Effects 0.000 claims abstract description 108
230000001225 therapeutic effect Effects 0.000 claims abstract description 79
102000004169 proteins and genes Human genes 0.000 claims abstract description 68
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 54
239000012634 fragment Substances 0.000 claims abstract description 40
230000001105 regulatory effect Effects 0.000 claims abstract description 35
210000004962 mammalian cell Anatomy 0.000 claims abstract description 29
239000003623 enhancer Substances 0.000 claims abstract description 25
108091008053 gene clusters Proteins 0.000 claims abstract description 6
210000004027 cell Anatomy 0.000 claims description 223
239000013598 vector Substances 0.000 claims description 90
108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 85
102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 64
208000015181 infectious disease Diseases 0.000 claims description 56
239000013612 plasmid Substances 0.000 claims description 51
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 37
208000005980 beta thalassemia Diseases 0.000 claims description 36
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 34
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
238000011282 treatment Methods 0.000 claims description 29
101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 claims description 27
210000004524 haematopoietic cell Anatomy 0.000 claims description 23
208000035475 disorder Diseases 0.000 claims description 21
230000002607 hemopoietic effect Effects 0.000 claims description 21
230000002950 deficient Effects 0.000 claims description 20
102000004190 Enzymes Human genes 0.000 claims description 18
108090000790 Enzymes Proteins 0.000 claims description 18
239000008194 pharmaceutical composition Substances 0.000 claims description 18
230000008488 polyadenylation Effects 0.000 claims description 18
210000005259 peripheral blood Anatomy 0.000 claims description 17
230000007812 deficiency Effects 0.000 claims description 16
239000003550 marker Substances 0.000 claims description 16
210000002798 bone marrow cell Anatomy 0.000 claims description 15
238000002512 chemotherapy Methods 0.000 claims description 15
210000005229 liver cell Anatomy 0.000 claims description 15
201000001320 Atherosclerosis Diseases 0.000 claims description 13
210000000130 stem cell Anatomy 0.000 claims description 13
230000000925 erythroid effect Effects 0.000 claims description 12
230000001580 bacterial effect Effects 0.000 claims description 11
230000001965 increasing effect Effects 0.000 claims description 10
239000011886 peripheral blood Substances 0.000 claims description 9
230000002093 peripheral effect Effects 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 claims description 8
101710172711 Structural protein Proteins 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 8
210000004700 fetal blood Anatomy 0.000 claims description 8
210000002950 fibroblast Anatomy 0.000 claims description 8
230000001575 pathological effect Effects 0.000 claims description 8
230000003612 virological effect Effects 0.000 claims description 8
208000007502 anemia Diseases 0.000 claims description 7
230000015572 biosynthetic process Effects 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
238000003786 synthesis reaction Methods 0.000 claims description 7
238000013518 transcription Methods 0.000 claims description 7
230000035897 transcription Effects 0.000 claims description 7
210000004881 tumor cell Anatomy 0.000 claims description 7
108091023040 Transcription factor Proteins 0.000 claims description 6
102000040945 Transcription factor Human genes 0.000 claims description 6
210000002889 endothelial cell Anatomy 0.000 claims description 6
210000001339 epidermal cell Anatomy 0.000 claims description 6
210000002919 epithelial cell Anatomy 0.000 claims description 6
210000003743 erythrocyte Anatomy 0.000 claims description 6
210000004602 germ cell Anatomy 0.000 claims description 6
210000000663 muscle cell Anatomy 0.000 claims description 6
208000026350 Inborn Genetic disease Diseases 0.000 claims description 5
238000012217 deletion Methods 0.000 claims description 5
230000037430 deletion Effects 0.000 claims description 5
102000034356 gene-regulatory proteins Human genes 0.000 claims description 5
108091006104 gene-regulatory proteins Proteins 0.000 claims description 5
150000003278 haem Chemical class 0.000 claims description 5
108010037414 Cytoskeletal Proteins Proteins 0.000 claims description 4
108010052285 Membrane Proteins Proteins 0.000 claims description 4
230000003436 cytoskeletal effect Effects 0.000 claims description 4
239000005556 hormone Substances 0.000 claims description 4
229940088597 hormone Drugs 0.000 claims description 4
238000003780 insertion Methods 0.000 claims description 4
230000037431 insertion Effects 0.000 claims description 4
108020003175 receptors Proteins 0.000 claims description 4
208000007056 sickle cell anemia Diseases 0.000 claims description 4
238000006467 substitution reaction Methods 0.000 claims description 4
108010059886 Apolipoprotein A-I Proteins 0.000 claims description 3
208000035473 Communicable disease Diseases 0.000 claims description 3
208000024556 Mendelian disease Diseases 0.000 claims description 3
230000003211 malignant effect Effects 0.000 claims description 3
208000023275 Autoimmune disease Diseases 0.000 claims description 2
101150074155 DHFR gene Proteins 0.000 claims description 2
101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 claims description 2
108700041567 MDR Genes Proteins 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims description 2
229930193140 Neomycin Natural products 0.000 claims description 2
101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 claims description 2
108010022394 Threonine synthase Proteins 0.000 claims description 2
229960004927 neomycin Drugs 0.000 claims description 2
101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 2
102000051062 human APOA1 Human genes 0.000 claims 2
208000030507 AIDS Diseases 0.000 claims 1
230000002159 abnormal effect Effects 0.000 claims 1
208000006454 hepatitis Diseases 0.000 claims 1
231100000283 hepatitis Toxicity 0.000 claims 1
239000000047 product Substances 0.000 description 52
238000000034 method Methods 0.000 description 51
210000000267 erythroid cell Anatomy 0.000 description 35
108091032973 (ribonucleotides)n+m Proteins 0.000 description 34
238000001415 gene therapy Methods 0.000 description 26
238000002474 experimental method Methods 0.000 description 25
238000004806 packaging method and process Methods 0.000 description 25
239000002299 complementary DNA Substances 0.000 description 20
210000001185 bone marrow Anatomy 0.000 description 19
239000000523 sample Substances 0.000 description 19
238000003556 assay Methods 0.000 description 16
230000001177 retroviral effect Effects 0.000 description 15
238000012546 transfer Methods 0.000 description 15
230000000694 effects Effects 0.000 description 13
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
238000010186 staining Methods 0.000 description 12
238000012360 testing method Methods 0.000 description 12
108010010234 HDL Lipoproteins Proteins 0.000 description 11
102000015779 HDL Lipoproteins Human genes 0.000 description 11
238000011161 development Methods 0.000 description 11
230000018109 developmental process Effects 0.000 description 11
230000010076 replication Effects 0.000 description 11
206010028980 Neoplasm Diseases 0.000 description 10
239000002609 medium Substances 0.000 description 10
230000002458 infectious effect Effects 0.000 description 9
TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 9
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
238000012258 culturing Methods 0.000 description 8
108060003196 globin Proteins 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
101710100588 Erythroid transcription factor Proteins 0.000 description 7
241001529936 Murinae Species 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
230000008901 benefit Effects 0.000 description 7
208000029078 coronary artery disease Diseases 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000002245 particle Substances 0.000 description 7
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
102100031690 Erythroid transcription factor Human genes 0.000 description 6
108091005903 Hemoglobin subunit delta Proteins 0.000 description 6
101150066553 MDR1 gene Proteins 0.000 description 6
108700026244 Open Reading Frames Proteins 0.000 description 6
241000700605 Viruses Species 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 6
210000005260 human cell Anatomy 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
229960001722 verapamil Drugs 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
238000001890 transfection Methods 0.000 description 5
241001430294 unidentified retrovirus Species 0.000 description 5
238000011144 upstream manufacturing Methods 0.000 description 5
229920002307 Dextran Polymers 0.000 description 4
206010059866 Drug resistance Diseases 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
102100039894 Hemoglobin subunit delta Human genes 0.000 description 4
241000699660 Mus musculus Species 0.000 description 4
239000000020 Nitrocellulose Substances 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
238000010276 construction Methods 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
230000007774 longterm Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000036457 multidrug resistance Effects 0.000 description 4
229920001220 nitrocellulos Polymers 0.000 description 4
230000008707 rearrangement Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000011830 transgenic mouse model Methods 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
ODPOAESBSUKMHD-UHFFFAOYSA-L 6,7-dihydrodipyrido[1,2-b:1',2'-e]pyrazine-5,8-diium;dibromide Chemical compound [Br-].[Br-].C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 ODPOAESBSUKMHD-UHFFFAOYSA-L 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
239000005630 Diquat Substances 0.000 description 3
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
208000002903 Thalassemia Diseases 0.000 description 3
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
229940009456 adriamycin Drugs 0.000 description 3
238000010171 animal model Methods 0.000 description 3
238000000211 autoradiogram Methods 0.000 description 3
210000003995 blood forming stem cell Anatomy 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229960001338 colchicine Drugs 0.000 description 3
210000004748 cultured cell Anatomy 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
108020001096 dihydrofolate reductase Proteins 0.000 description 3
238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
238000001476 gene delivery Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
102000018146 globin Human genes 0.000 description 3
102000053576 human ABCB1 Human genes 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
230000035772 mutation Effects 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
229960003048 vinblastine Drugs 0.000 description 3
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
102000055025 Adenosine deaminases Human genes 0.000 description 2
102000005666 Apolipoprotein A-I Human genes 0.000 description 2
108090000565 Capsid Proteins Proteins 0.000 description 2
102100023321 Ceruloplasmin Human genes 0.000 description 2
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 2
102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
208000036566 Erythroleukaemia Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
108091005886 Hemoglobin subunit gamma Proteins 0.000 description 2
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
206010021024 Hypolipidaemia Diseases 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000000853 LDL receptors Human genes 0.000 description 2
108010001831 LDL receptors Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
108091092724 Noncoding DNA Proteins 0.000 description 2
XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
239000013614 RNA sample Substances 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
206010038997 Retroviral infections Diseases 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
101100288046 Streptomyces hygroscopicus hyg gene Proteins 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
208000021841 acute erythroid leukemia Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000010195 expression analysis Methods 0.000 description 2
208000016361 genetic disease Diseases 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
230000012010 growth Effects 0.000 description 2
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
229940097277 hygromycin b Drugs 0.000 description 2
208000029498 hypoalphalipoproteinemia Diseases 0.000 description 2
238000000760 immunoelectrophoresis Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
208000004235 neutropenia Diseases 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002028 premature Effects 0.000 description 2
230000009711 regulatory function Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
101150084750 1 gene Proteins 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
108700012841 Cholesteryl Ester Transfer Protein Deficiency Proteins 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
241000760358 Enodes Species 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
206010016275 Fear Diseases 0.000 description 1
240000006829 Ficus sundaica Species 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
101710166347 Globin-5 Proteins 0.000 description 1
102000004547 Glucosylceramidase Human genes 0.000 description 1
108010017544 Glucosylceramidase Proteins 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
101710128836 Large T antigen Proteins 0.000 description 1
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
239000007984 Tris EDTA buffer Substances 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
208000037741 atherosclerosis susceptibility Diseases 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
-1 cholesteryl ester Chemical class 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003013 erythroid precursor cell Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
231100000206 health hazard Toxicity 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
208000015076 hyperalphalipoproteinemia Diseases 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000000738 kidney tubule Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229960001539 poliomyelitis vaccine Drugs 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000007447 staining method Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
239000013603 viral vector Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL10955894A 1994-05-04 1994-05-04 מבני ד.נ.א. הנגזרים מוירוס sv40 הכוללים רצפי ד.נ.א. חיצוניים IL109558A (he)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
IL10955894A IL109558A (he)	1994-05-04	1994-05-04	מבני ד.נ.א. הנגזרים מוירוס sv40 הכוללים רצפי ד.נ.א. חיצוניים
AU24350/95A AU2435095A (en)	1994-05-04	1995-05-04	Sv-40 derived dna constructs comprising exogenous dna sequences
CA002189582A CA2189582A1 (en)	1994-05-04	1995-05-04	Sv-40 derived dna constructs comprising exogenous dna sequences
EP95918395A EP0772688A1 (en)	1994-05-04	1995-05-04	Sv-40 derived dna constructs comprising exogenous dna sequences
US08/737,047 US6090608A (en)	1994-05-04	1995-05-04	SV-40 derived DNA constructs comprising exogenous DNA sequences
PCT/US1995/005595 WO1995030762A1 (en)	1994-05-04	1995-05-04	Sv-40 derived dna constructs comprising exogenous dna sequences
GB9622965A GB2303137A (en)	1994-05-04	1995-05-04	Sv40-derived dna constructs comprising exogenous dna sequences

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL10955894A IL109558A (he)	1994-05-04	1994-05-04	מבני ד.נ.א. הנגזרים מוירוס sv40 הכוללים רצפי ד.נ.א. חיצוניים

Publications (2)

Publication Number	Publication Date
IL109558A0 IL109558A0 (en)	1994-08-26
IL109558A true IL109558A (he)	2004-08-31

Family

ID=11066106

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10955894A IL109558A (he)	1994-05-04	1994-05-04	מבני ד.נ.א. הנגזרים מוירוס sv40 הכוללים רצפי ד.נ.א. חיצוניים

Country Status (7)

Country	Link
US (1)	US6090608A (he)
EP (1)	EP0772688A1 (he)
AU (1)	AU2435095A (he)
CA (1)	CA2189582A1 (he)
GB (1)	GB2303137A (he)
IL (1)	IL109558A (he)
WO (1)	WO1995030762A1 (he)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4649396A (en) *	1994-12-30	1996-07-24	Thomas Jefferson University	Gene transduction system
US7279313B2 (en)	1995-09-15	2007-10-09	Centelion	Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) *	1995-09-15	1997-10-31	Rhone Poulenc Rorer Sa	Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7364894B2 (en)	1995-09-15	2008-04-29	Centelion	Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
JP2004537539A (ja)	2001-06-29	2004-12-16	スローン − ケッタリングインスティチュートフォーキャンサーリサーチ	ヒトグロビン遺伝子をコードするベクターとその異常ヘモグロビン血症の治療におけるその使用
DK1919954T3 (en)	2005-08-30	2017-01-30	Univ Miami	Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins
IL176377A0 (en) *	2006-06-18	2006-10-05	Ariella Oppenheim	Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders
ES2586837T3 (es)	2009-08-03	2016-10-19	University Of Miami	Método para la expansión in vivo de linfocitos T reguladores
LT2673296T (lt)	2011-02-07	2019-02-25	Cerenis Therapeutics Holding Sa	Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
EP2943253B1 (en)	2013-01-09	2021-10-20	University Of Miami	Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein and il-2
WO2016144642A1 (en) *	2015-03-06	2016-09-15	Chromologic Llc	Genetically engineered host cells for malaria research

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4396601A (en) *	1980-03-26	1983-08-02	The Regents Of The University Of Calif.	Gene transfer in intact mammals
US5399346A (en) *	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy

1994
- 1994-05-04 IL IL10955894A patent/IL109558A/he not_active IP Right Cessation
1995
- 1995-05-04 EP EP95918395A patent/EP0772688A1/en not_active Withdrawn
- 1995-05-04 WO PCT/US1995/005595 patent/WO1995030762A1/en not_active Ceased
- 1995-05-04 GB GB9622965A patent/GB2303137A/en not_active Withdrawn
- 1995-05-04 AU AU24350/95A patent/AU2435095A/en not_active Abandoned
- 1995-05-04 US US08/737,047 patent/US6090608A/en not_active Expired - Fee Related
- 1995-05-04 CA CA002189582A patent/CA2189582A1/en not_active Abandoned

Also Published As

Publication number	Publication date
GB2303137A (en)	1997-02-12
GB9622965D0 (en)	1997-01-08
CA2189582A1 (en)	1995-11-16
IL109558A0 (en)	1994-08-26
US6090608A (en)	2000-07-18
EP0772688A1 (en)	1997-05-14
AU2435095A (en)	1995-11-29
WO1995030762A1 (en)	1995-11-16

Legal Events

Date	Code	Title
2005-01-24	FF	Patent granted
2005-02-20	KB	Patent renewed
2006-01-15	HP	Change in proprietorship
2008-08-10	KB	Patent renewed
2012-12-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
Brown et al.	1986	A recombinant murine retrovirus for simian virus 40 large T cDNA transforms mouse fibroblasts to anchorage-independent growth
JP4390860B2 (ja)	2009-12-24	レンチウイルスをベースにした遺伝子転移ベクター
US6555674B2 (en)	2003-04-29	JeT promoter
EP0832980B1 (en)	2002-06-19	Recombinant therapies for infection and hyperproliferative disorders
JP2859252B2 (ja)	1999-02-17	感染および過剰増殖障害の為の組換え療法
JP3082204B2 (ja)	2000-08-28	両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5770374A (en)	1998-06-23	Methods for identifying oncogenes and anti-oncogenes
US6261834B1 (en)	2001-07-17	Vector for gene therapy
WO1993000103A1 (en)	1993-01-07	Chimeric envelope proteins for viral targeting
JPH06504680A (ja)	1994-06-02	遺伝子療法のための安全ベクター
US6090608A (en)	2000-07-18	SV-40 derived DNA constructs comprising exogenous DNA sequences
CA2124769C (en)	2007-07-10	Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors
JP2000514652A (ja)	2000-11-07	産生能力の高いカプシド化系
DE69332045T2 (de)	2002-10-17	Hepatistherapeutikum
WO1995034639A1 (en)	1995-12-21	Novel retroviral envelope and ltr and retroviral vector particles including such envelope and/or ltr
JPH09511405A (ja)	1997-11-18	レトロウイルスベクターハイブリッド及びその遺伝子転移のための使用
AU693317B2 (en)	1998-06-25	Retroviral vectors for expression in embryonic cells
DE69527544T2 (de)	2003-03-20	Kombinationsvektoren zum austragen von genmaterial
Inouye et al.	1997	Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector
Peng et al.	1997	Construction of recombinant adeno-associated virus vector containing the rat preproinsulin II gene
AU5138293A (en)	1994-04-12	Recombinant retroviral vector against felv and/or fiv
WO1999036559A1 (en)	1999-07-22	Viral vectors expressing self-polymerizing neuronal intermediate filaments and their use
Yu	1987	DEVELOPING RETROVIRAL VECTORS FOR EFFICIENT GENE TRANSFER AND EXPRESSION IN HUMAN GENE THERAPY
WO1997002841A1 (en)	1997-01-30	Genetic therapy employing the hhv-6a derived ts gene or polypeptide
JP2008237216A (ja)	2008-10-09	ワクチン評価のための動物モデル